Antares Pharma Appoints David H. Bergstrom Ph.D. as Senior Vice President Pharmaceutical Development
November 19 2013 - 7:00AM
Business Wire
Antares Pharma, Inc. (NASDAQ:ATRS) today announced the
appointment of David H. Bergstrom Ph.D. to the position of Senior
Vice President of Pharmaceutical Development. Dr. Bergstrom is an
experienced, operations focused executive with a leadership
background in large, small and semi-virtual pharmaceutical
companies as well as in the contract product development and
manufacturing industry. He received his Ph.D. in Pharmaceutics from
the University of Utah, Salt Lake City, Utah.
Dr. Bergstrom comes to Antares Pharma from Advantar Laboratories
where he was the Executive Vice President and Chief Operating
Officer. Prior to joining Advantar, he was the Senior Vice
President and COO for NovaDel Pharmaceuticals. Dr. Bergstrom
previously served as Senior Vice President and General Manager of
the Pharmaceutical Development business of Cardinal Health, Inc.
Prior to Cardinal Health, Dr. Bergstrom served as Vice President of
Pharmaceutical and Chemical Development at Guilford Pharmaceuticals
and also served in senior positions in preclinical development and
pharmaceutical and analytical development at Hoechst-Roussel
Pharmaceuticals, Inc., predecessor companies of Sanofi-Aventis
Pharmaceuticals, Inc. Prior to that, Dr. Bergstrom worked in
pharmaceutical development at CIBA-Geigy Pharmaceuticals, Inc.
“We are very pleased to welcome Dr. Bergstrom to the Antares
team,” said Paul K. Wotton, Ph.D., President and Chief Executive
Officer. “David has a proven track record as a leader of product
development teams and has worked on multiple FDA approved products
including 505B2 drug/device combination programs. His broad product
development expertise will help drive our pipeline initiative and
insure that we continue to execute our programs aggressively and
expedite future product launches such as Quick Shot™ testosterone
and QS M.”
About Antares Pharma
Antares Pharma focuses on self-administered parenteral
pharmaceutical products and topical gel-based medicines. The
Company has received marketing approval from the U.S. Food and Drug
Administration for OTREXUP™ (methotrexate) injection for the
treatment of adults with severe active rheumatoid arthritis,
children with active polyarticular juvenile idiopathic arthritis
and adults with severe recalcitrant psoriasis. Antares Pharma is
also developing VIBEX® QS T for testosterone replacement therapy.
The Company's technology platforms include VIBEX® disposable
Medi-Jet, disposable multi-use pen injectors and Vision™ reusable
needle-free injectors marketed as Tjet® and Zomajet® by Teva
Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals
(Ferring), respectively. Antares Pharma has a multi-product deal
with Teva that includes Tev-Tropin® [somatropin (rDNA origin) for
injection] human growth hormone (hGH), VIBEX® epinephrine and
several other products. Antares Pharma’s partnership with Ferring
includes Zomacton® hGH (somatropin) injection. In the U.S. Antares
has received FDA approval for Gelnique 3%™ (oxybutynin) gel, a
treatment for overactive bladder that is marketed by Actavis.
Elestrin® (estradiol gel) is FDA approved for the treatment of
moderate-to-severe vasomotor symptoms associated with menopause,
and is marketed in the U.S. by Meda Pharma. Antares Pharma has two
facilities in the U.S. The Parenteral Products Group located in
Minneapolis, Minnesota directs the manufacturing and marketing of
the Company’s reusable needle-free injection devices and related
disposables, and develops its disposable pressure-assisted Medi-Jet
and pen injector systems. The Company’s corporate office and
Product Development and Commercial Groups are located in Ewing, New
Jersey.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These statements are indicated by
the words “may,” “will,” “plans,” “intends,” “believes,” “expects,”
“anticipates,” “potential,” “could,” “would,” “should,” and similar
expressions. Such forward-looking statements are not guarantees of
future performance and are subject to risks and uncertainties that
may cause actual results to differ materially from those
anticipated by the forward-looking statements. These risks and
uncertainties include, among others, changes in revenue growth and
difficulties or delays in the commercial launch of OTREXUP™, market
acceptance by physicians and patients of new products, delays in
product development and changes or delays in the regulatory process
for existing or new product candidates. In addition, the Quick
Shot™ testosterone and the QS M products referred to in this press
release have not yet been approved by the FDA, and the
commercialization of Quick Shot testosterone and QS M are dependent
on the FDA approving these products. Additional information
concerning these and other factors that may cause actual results to
differ materially from those anticipated in the forward-looking
statements is contained in the "Risk Factors" section of the
Company's Annual Report on Form 10-K for the year ended December
31, 2012, and in the Company's other periodic reports and filings
with the Securities and Exchange Commission. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in this press release. All forward-looking
statements are based on information currently available to the
Company on the date hereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to
reflect events or circumstances after the date of this press
release, except as required by law.
Investor:Antares Pharma, Inc.Jack Howarth,
609-359-3016Vice President, Corporate
Affairsjhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024